DearEditors-in-Chief,We read with interest the paper by Su et al.(2025)describing a soil incubation study.The paper provides useful data on the effect of wollastonite addition on CO_(2)emission/capture and soil proper...DearEditors-in-Chief,We read with interest the paper by Su et al.(2025)describing a soil incubation study.The paper provides useful data on the effect of wollastonite addition on CO_(2)emission/capture and soil properties.However,one of the main conclusions appears to directly contradict the data,perpetuating the unsupported notion that a significant amount of CO_(2)is captured during weathering of crushed silicate rockmixed into acidicsoil.展开更多
Clinical Question How to choose the drugs of adjuvant therapy for nonsmall-cell lung cancer(NSCLC)patients harboring driver gene mutation?Recommendations Recommendation 1:We suggest osimertinib(80 mg)adjuvant therapy ...Clinical Question How to choose the drugs of adjuvant therapy for nonsmall-cell lung cancer(NSCLC)patients harboring driver gene mutation?Recommendations Recommendation 1:We suggest osimertinib(80 mg)adjuvant therapy in stage Ib–IIIa EGFR-positive(Ex19del or L858R)NSCLC patients after surgery.According to the results of the ADAURA study,the benefit of osimertinib administration increases with advancing tumor stage.(Strong recommendation,high certainty of evidence)展开更多
文摘DearEditors-in-Chief,We read with interest the paper by Su et al.(2025)describing a soil incubation study.The paper provides useful data on the effect of wollastonite addition on CO_(2)emission/capture and soil properties.However,one of the main conclusions appears to directly contradict the data,perpetuating the unsupported notion that a significant amount of CO_(2)is captured during weathering of crushed silicate rockmixed into acidicsoil.
文摘Clinical Question How to choose the drugs of adjuvant therapy for nonsmall-cell lung cancer(NSCLC)patients harboring driver gene mutation?Recommendations Recommendation 1:We suggest osimertinib(80 mg)adjuvant therapy in stage Ib–IIIa EGFR-positive(Ex19del or L858R)NSCLC patients after surgery.According to the results of the ADAURA study,the benefit of osimertinib administration increases with advancing tumor stage.(Strong recommendation,high certainty of evidence)
